Opportunity to generate competition in the biologics space with more than 1400 biosimilar approvals covering over 10 therapeutic areas



A. Canada
B. USA
C. Mexico
D. Brazil
E. Argentina
F. European Union
G. Switzerland
H. Serbia
I. Montenegro
J. Jordan
K. Saudi Arabia
L. Morocco
M. Japan
N. South Korea
O. India
P. Malaysia
Q. Chinese Taipei
R. Australia

Total biosimilars approved in all strengths and forms per INN

IGBA
INTERNATIONAL GENERIC AND BIOSIMILAR MEDICINES ASSOCIATION

Source of data: IGBA membership and National Regulatory Authorities